Show simple item record

dc.contributor.authorThivierge, Karine
dc.contributor.authorMathew, Rency T
dc.contributor.authorNsangou, Desire MM
dc.contributor.authorDa Silva, Fabio
dc.contributor.authorCotton, Sophie
dc.contributor.authorSkinner-Adams, Tina S
dc.contributor.authorTrenholme, Katharine R
dc.contributor.authorBrown, Christopher L
dc.contributor.authorStack, Colin M
dc.contributor.authorGardiner, Donald L
dc.contributor.authorDalton, John P
dc.date.accessioned2017-05-03T11:28:11Z
dc.date.available2017-05-03T11:28:11Z
dc.date.issued2012
dc.date.modified2013-06-03T01:31:39Z
dc.identifier.issn1551-7004
dc.identifier.doi10.3998/ark.5550190.0013.424
dc.identifier.urihttp://hdl.handle.net/10072/50265
dc.description.abstractThe M1 alanyl aminopeptidase and M17 leucyl aminopeptidase are critical to the growth and development of malaria parasites inside host erythrocytes. Potent aminopeptidase inhibitors kill malaria parasites in culture and are also active in vivo against murine malaria. Functional recombinant enzyme studies have been used to decipher the three-dimensional structures of both enzymes that together with new and specific inhibitors are facilitating structure-activity-relationship (SAR) and functional studies. Here we review the progress made in our knowledge of these two enzymes which is bringing them closer to being validated anti-malarial drug targets.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.format.extent339858 bytes
dc.format.mimetypeapplication/pdf
dc.languageEnglish
dc.language.isoeng
dc.publisherARKAT
dc.publisher.placeUnited States
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom330
dc.relation.ispartofpageto346
dc.relation.ispartofissue4
dc.relation.ispartofjournalARKIVOC
dc.relation.ispartofvolume2012
dc.rights.retentionY
dc.subject.fieldofresearchMedicinal and biomolecular chemistry
dc.subject.fieldofresearchBiologically active molecules
dc.subject.fieldofresearchProteins and peptides
dc.subject.fieldofresearchOrganic chemistry
dc.subject.fieldofresearchcode3404
dc.subject.fieldofresearchcode340401
dc.subject.fieldofresearchcode340407
dc.subject.fieldofresearchcode3405
dc.titleAnti-malaria drug development targeting the M1 alanyl and M17 leucyl aminopeptidases
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
dcterms.licensehttp://creativecommons.org/licenses/by/3.0/
gro.rights.copyright© The Author(s) 2012. This is an Open Access article distributed under the terms of the Creative Commons Attribution 3.0 License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
gro.date.issued2012
gro.hasfulltextFull Text
gro.griffith.authorSkinner-Adams, Tina


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record